4502
Takeda Pharmaceutical Company$27.00
4502 info0.21%ย โ€ข 24 H
Dividend Yield:4.2%
Global Rank#416
Market Cap$41.91B
YTD Performance3.09%
P/E0.13
Revenue$25.65B
Change 7d2.64%
SP500 BenchmarkUnderperform
P/S1.63
Earnings$2.02B

Takeda Pharmaceutical Company (4502) Stock Overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

4502 Stock Information

Symbol4502
Address
1-1, Nihonbashi-Honcho 2-chomeTokyo, 103-8668Japan
Founded-
Trading hours-
Websitehttps://www.takeda.com
Country๐Ÿ‡ฏ๐Ÿ‡ต Japan
Phone Number81 3 3278 2111

Takeda Pharmaceutical Company (4502) Price Chart

-
Value:-

Takeda Pharmaceutical Company Overview: Key Details and Summary

Stock data
2023
Change
Price
$27.00
N/A
Market Cap
$41.91B
N/A
Shares Outstanding
1.55B
-0.75%
Employees
49.09K
N/A
Shareholder Equity
6.35T
11.81%
Valuation
2023
Change
P/E Ratio
0.13
N/A
P/S Ratio
1.63
N/A
P/B Ratio
0.01
N/A
P/FCF
19.16
N/A
POE
0.00
N/A
Dividends
2023
Change
Dividend Yield
4.25%
N/A
Dividend per share
1.1465
N/A
Dividend Payout Ratio
0.8813
N/A
Growth
2023
Change
ROIC
0.0963
N/A
CAPEX
-889.52M
N/A
Return on Equity
0.0003
N/A
Earnings
2023
Change
Revenue
$25.65B
N/A
Earnings
$2.02B
N/A
Free Cash Flow
$2.19B
N/A
EPS
201.94
N/A
Earnings Yield
7.48
N/A
Gross Margin
0.6911
N/A
Operating Margin
0.1373
N/A
Net income margin
0.0787
N/A
FCF Margin
0.0853
N/A
Financial Strength
2023
Change
Total Assets
$88.88B
N/A
Total Debt
$27.91B
N/A
Cash on Hand
$3.53B
N/A
Debt to Equity
0.0076
-9.27%
Cash to Debt
0.1263
-37.25%
POE
0.0000
N/A
Current Ratio
0.9662
-20.07%
Other data
2023
Change
Buyback Yield
0.0041
N/A
ยฉ 2024 TopStocks.org
Facebook Icon
Twitter Icon
Linkedin Icon